140 related articles for article (PubMed ID: 7517074)
1. Masking of heparin activity in the activated coagulation time (ACT) by platelet procoagulant activity.
Bode AP; Lust RM
Thromb Res; 1994 Mar; 73(5):285-300. PubMed ID: 7517074
[TBL] [Abstract][Full Text] [Related]
2. The effect of lysed platelets on neutralization of heparin in vitro with protamine as measured by the activated coagulation time (ACT).
Bode AP; Castellani WJ; Hodges ED; Yelverton S
Thromb Haemost; 1991 Aug; 66(2):213-7. PubMed ID: 1771614
[TBL] [Abstract][Full Text] [Related]
3. Effects of aprotinin on anticoagulant monitoring: implications in cardiovascular surgery.
Najman DM; Walenga JM; Fareed J; Pifarré R
Ann Thorac Surg; 1993 Mar; 55(3):662-6. PubMed ID: 7680854
[TBL] [Abstract][Full Text] [Related]
4. Protamine reversal of heparin affects platelet aggregation and activated clotting time after cardiopulmonary bypass.
Mochizuki T; Olson PJ; Szlam F; Ramsay JG; Levy JH
Anesth Analg; 1998 Oct; 87(4):781-5. PubMed ID: 9768770
[TBL] [Abstract][Full Text] [Related]
5. Heparin neutralization by recombinant platelet factor 4 and protamine.
Levy JH; Cormack JG; Morales A
Anesth Analg; 1995 Jul; 81(1):35-7. PubMed ID: 7598278
[TBL] [Abstract][Full Text] [Related]
6. Lysed platelets shorten the activated coagulation time (ACT) of heparinized blood.
Bode AP; Eick L
Am J Clin Pathol; 1989 Apr; 91(4):430-4. PubMed ID: 2929497
[TBL] [Abstract][Full Text] [Related]
7. Prolonged Activated Clotting Time after Protamine Administration Does Not Indicate Residual Heparinization after Cardiopulmonary Bypass in Pediatric Open Heart Surgery.
Yamamoto T; Wolf HG; Sinzobahamvya N; Asfour B; Hraska V; Schindler E
Thorac Cardiovasc Surg; 2015 Aug; 63(5):397-403. PubMed ID: 26121380
[TBL] [Abstract][Full Text] [Related]
8. The impact of heparin concentration and activated clotting time monitoring on blood conservation. A prospective, randomized evaluation in patients undergoing cardiac operation.
Despotis GJ; Joist JH; Hogue CW; Alsoufiev A; Kater K; Goodnough LT; Santoro SA; Spitznagel E; Rosenblum M; Lappas DG
J Thorac Cardiovasc Surg; 1995 Jul; 110(1):46-54. PubMed ID: 7609568
[TBL] [Abstract][Full Text] [Related]
9. Heparin detection by the activated coagulation time: a comparison of the sensitivity of coagulation tests and heparin assays.
Murray DJ; Brosnahan WJ; Pennell B; Kapalanski D; Weiler JM; Olson J
J Cardiothorac Vasc Anesth; 1997 Feb; 11(1):24-8. PubMed ID: 9058215
[TBL] [Abstract][Full Text] [Related]
10. Recombinant platelet factor 4 reversal of heparin in human cardiopulmonary bypass blood.
Williams RD; D'Ambra MN; Maione TE; Lynch KE; Keene DF
J Thorac Cardiovasc Surg; 1994 Nov; 108(5):975-83. PubMed ID: 7967683
[TBL] [Abstract][Full Text] [Related]
11. Platelet involvement in the activated coagulation time of heparinized blood.
Moorehead MT; Westengard JC; Bull BS
Anesth Analg; 1984 Apr; 63(4):394-8. PubMed ID: 6367544
[TBL] [Abstract][Full Text] [Related]
12. The relationship between hirudin and activated clotting time: implications for patients with heparin-induced thrombocytopenia undergoing cardiac surgery.
Despotis GJ; Hogue CW; Saleem R; Bigham M; Skubas N; Apostolidou I; Qayum A; Joist JH
Anesth Analg; 2001 Jul; 93(1):28-32. PubMed ID: 11429333
[TBL] [Abstract][Full Text] [Related]
13. Detection of protamine and heparin after termination of cardiopulmonary bypass by thrombelastometry (ROTEM): results of a pilot study.
Mittermayr M; Velik-Salchner C; Stalzer B; Margreiter J; Klingler A; Streif W; Fries D; Innerhofer P
Anesth Analg; 2009 Mar; 108(3):743-50. PubMed ID: 19224778
[TBL] [Abstract][Full Text] [Related]
14. Influence of heparin, heparin plus aprotinin and hirudin on contact activation in a cardiopulmonary bypass model.
Wendel HP; Heller W; Gallimore MJ
Immunopharmacology; 1996 May; 32(1-3):57-61. PubMed ID: 8796267
[TBL] [Abstract][Full Text] [Related]
15. A case series of recombinant platelet factor 4 for heparin reversal after cardiopulmonary bypass.
Demma L; Levy JH
Anesth Analg; 2012 Dec; 115(6):1273-8. PubMed ID: 22859690
[TBL] [Abstract][Full Text] [Related]
16. Aprotinin counteracts heparin-induced inhibition of platelet contractile force.
Carr ME; Carr SL; Roa V; McCardell KA; Greilich PE
Thromb Res; 2002 Nov; 108(2-3):161-8. PubMed ID: 12590953
[TBL] [Abstract][Full Text] [Related]
17. Anticoagulation and anticoagulation reversal with cardiac surgery involving cardiopulmonary bypass: an update.
Despotis GJ; Joist JH
J Cardiothorac Vasc Anesth; 1999 Aug; 13(4 Suppl 1):18-29; discussion 36-7. PubMed ID: 10468245
[TBL] [Abstract][Full Text] [Related]
18. Heparin dosing and monitoring for cardiopulmonary bypass. A comparison of techniques with measurement of subclinical plasma coagulation.
Gravlee GP; Haddon WS; Rothberger HK; Mills SA; Rogers AT; Bean VE; Buss DH; Prough DS; Cordell AR
J Thorac Cardiovasc Surg; 1990 Mar; 99(3):518-27. PubMed ID: 2308370
[TBL] [Abstract][Full Text] [Related]
19. The role of the activated clotting time in heparin administration and neutralization for cardiopulmonary bypass.
Esposito RA; Culliford AT; Colvin SB; Thomas SJ; Lackner H; Spencer FC
J Thorac Cardiovasc Surg; 1983 Feb; 85(2):174-85. PubMed ID: 6823136
[TBL] [Abstract][Full Text] [Related]
20. r-Hirudin inhibits platelet-dependent thrombosis during cardiopulmonary bypass in baboons.
van Wyk V; Neethling WM; Badenhorst PN; Kotzé HF
J Cardiovasc Surg (Torino); 1998 Oct; 39(5):633-9. PubMed ID: 9833724
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
